Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer

Wednesday, May 29, 2024 1 min read

Key Takeaway: Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer

Full Press Release Details

Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer.